Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New speech therapy shows promise for kids with apraxia

NCT ID NCT03903120

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a speech therapy called ASSIST for children aged 4 to 9 with childhood apraxia of speech, a disorder that makes it hard to plan speech movements. Fifty-one children received 16 hours of individual therapy using repetition and cues. The goal was to see if the therapy improves speech accuracy and everyday communication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ASSIST (a behavioral speech therapy using repetition and cues)
What this could lead to
If successful, this could point toward a more effective therapy for children with apraxia of speech, improving their ability to speak clearly.
What could go wrong
This is an early Phase 1 study with only 51 children, so results may not apply to all. The therapy is intensive and may not work for every child.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

51 people

The number who actually took part.

Started

Apr 2019

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 9 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 4;0 and 9;11 (years;months) at enrollment, based on parent report. 2. From homes where the primary language spoken is English, based on parent report. 3. Verbal output (50+ words) and communicative intent, as determined by the clinician and parent report. 4. Speech sound disorder, as determined by a score \<16th percentile on the Diagnostic Evaluation of Articulation and Phonology (DEAP) Articulation Assessment (Dodd et al., 2006) and/or the Goldman-Fristoe Test of Articulation (Goldman \& Fristoe, 2015). 5. CAS as a primary speech diagnosis, based on the following criteria: 1. An average rating \> 1 across three expert speech-language pathologists (SLPs), who will independently rate presence of CAS in children live or from video recordings of the assessment using a 3-point scale (0 = no CAS, 1 = possible CAS, 2 = CAS). These judgments will be based on perceptual speech features of CAS (inconsistent vowel and consonant errors, difficulties achieving and transitioning into articulatory configurations, abnormal prosody). 2. An Apraxia Score of 1 or 2 on a Maximum Performance protocol in which they sustain vowels and fricatives as long as possible and repeat syllables as fast as possible (Rvachew et al., 2005; Thoonen et al., 1999). 6. Normal hearing based on parent report or passing a standard pure-tone audiometry hearing screening at 500, 1000, 2000, and 4000 Hz (ASHA, 1997). 7. Typical nonverbal cognition as determined by a T-score within 1.5 standard deviation (SD) of the mean on nonverbal subtests of the Reynolds Intellectual Assessment Scales (Reynolds \& Kamphaus, 2003). Exclusion Criteria: 1. Diagnosis of disorder that significantly affects communication and/or social interactions (e.g., autism), as per referral diagnosis. 2. Uncorrected vision impairments that may interfere with ability to process visual cues used in treatment, as per parent report. 3. Significant impairments of oral structure (e.g., cleft palate) as judged by the SLP based on an oral mechanism exam (Robbins \& Klee, 1987). 4. A primary diagnosis of dysarthria, as judged by the SLP. 5. Unrelated health concerns that prevent children from participating, per parent report. 6. Inability to meet toileting needs independently or separate from parent for a full day (as needed for camp), based on parent report.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood apraxia of speech are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Temple University

    Philadelphia, Pennsylvania, 19122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.